PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
55 hedge funds and large institutions have $113M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
55
Holding in Top 10
–
Calls
$119K
Puts
$45K
Top Buyers
| 1 | +$2.3M | |
| 2 | +$1.11M | |
| 3 | +$1.08M | |
| 4 |
Millennium Management
New York
|
+$772K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$339K |
Top Sellers
| 1 | -$2.72M | |
| 2 | -$2.6M | |
| 3 | -$1.38M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$987K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$985K |